الفهرس 
A- EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Breast cancer is the most common cancer worldwide
for females, and the 2nd most common cancer overall
(Ferlay et al., 2013). miRNAs may be exploited as a new
kind of molecular markers for follow up of breast cancer
(Zeng et al., 2014).
This study was carried out at medical biochemistry
Department, in collaboration with General surgery
Department, Faculty of Medicine, Ain Shams University,
and was approved by the research ethical committee of
Faculty of Medicine, Ain Shams University during the
years (2013-2014). The study included 58 female.
Participants were classified into two groups.
Group A, consisted of thirty eight females with
histopathologicaly confirmed malignant breast tumors.
Breast cancer patients underwent either breast conserving
surgery or modified radical mastectomy. Patients who had
received any chemotherapy or radiation therapy before
surgery or who had rheumatic disease, acute infection, or
other types of cancer were excluded from the current study.
Clinical staging of breast cancer was performed according
to TNM classification (AJCC, 2010).
Summary, Conclusion & Recommendation
132
Group B, consisted of twenty females who underwent
breast reduction as a control group. They were recruited
from plastic surgery department, Faculty of medicine, Ain
shams university.
The aim of the present study was to investigate the
synergistic expression of miR-96 and miR-155 in breast
cancer and to evaluate their efficacy as potential prognostic
markers using quantitative real-time PCR.
Quantitative real-time PCR is considered as the gold
standard for measuring of miRNAs levels (Schmittgen et
al., 2008).
Our results revealed the following:
The expression level of each of miRNA (96 and 155)
was significantly higher in breast cancer than normal
control tissues.
The sensitivity of miR-96 expression in breast cancer
tissue was significantly higher (86.8%) than miR-155
(78.9%). Meanwhile, the specificity of each of them was
the same (95%).
The expression of miR-96 and miR-155 was
significantly higher in advanced stage and lymph node
metastasis in breast cancer group.
Summary, Conclusion & Recommendation
133
The high expression of miR-155 in premenopausal
patients with breast cancer may give better
understanding about the mechanism of the currently
used antiestrogen therapy.
On combining miR-96 and miR-155, the sensitivity was
increased to reach 92.1% whereas, the specificity
remained the same.
Expression of miR-96 could be influenced by miR-155
expression as shown in 93.3% of breast cancer tissues
included in our study.
These current findings could propose the idea that
analysis of combined expression of miR-96 and miR-155
may be of prognostic value in breast cancer.
Recommendations
It would be interesting to analyze the expression
profile of these two miRNAs together in serum, (or plasma)
of breast cancer patients looking for a non invasive
diagnostic tool.
Further research concerning the potential use of miR-
96 and miR-155 as therapeutic targets in breast cancer
treatment is urgently needed